Hazard ratios for NRM and OS by multivariate regression
| Predictor (n) . | NRM . | OS . | ||
|---|---|---|---|---|
| HR . | P . | HR . | P . | |
| HCT-CI score | ||||
| 0 (n = 1119) | 1 | 1 | ||
| 1-2 (n = 441) | 1.54 | < .001 | 1.29 | .009 |
| ≥ 3 (n = 377) | 1.90 | < .000 | 1.93 | < .000 |
| High-risk disease (n = 1355) vs low-risk | 1.62 | < .000 | 1.75 | < .000 |
| Age > 50 y (n = 824) | 1.33 | .008 | 1.25 | .004 |
| Myeloablative regimen (n = 1083) vs RIC | 1.04 | .675 | 1.33 | .002 |
| PBSC (n = 1466) vs bone marrow | 1.03 | .813 | 0.98 | .910 |
| Male sex (n = 1108) vs female | 0.87 | .234 | 1.00 | .925 |
| Unrelated donor (n = 979) vs related | 2.01 | < .000 | 1.38 | < .000 |
| Female donor/male recipient (n = 390) vs other | 1.07 | .571 | 1.00 | .952 |
| CMV serostatus donor−/recipient− (n = 192) vs other | 0.92 | .592 | 0.86 | .171 |
| Predictor (n) . | NRM . | OS . | ||
|---|---|---|---|---|
| HR . | P . | HR . | P . | |
| HCT-CI score | ||||
| 0 (n = 1119) | 1 | 1 | ||
| 1-2 (n = 441) | 1.54 | < .001 | 1.29 | .009 |
| ≥ 3 (n = 377) | 1.90 | < .000 | 1.93 | < .000 |
| High-risk disease (n = 1355) vs low-risk | 1.62 | < .000 | 1.75 | < .000 |
| Age > 50 y (n = 824) | 1.33 | .008 | 1.25 | .004 |
| Myeloablative regimen (n = 1083) vs RIC | 1.04 | .675 | 1.33 | .002 |
| PBSC (n = 1466) vs bone marrow | 1.03 | .813 | 0.98 | .910 |
| Male sex (n = 1108) vs female | 0.87 | .234 | 1.00 | .925 |
| Unrelated donor (n = 979) vs related | 2.01 | < .000 | 1.38 | < .000 |
| Female donor/male recipient (n = 390) vs other | 1.07 | .571 | 1.00 | .952 |
| CMV serostatus donor−/recipient− (n = 192) vs other | 0.92 | .592 | 0.86 | .171 |
RIC indicates reduced-intensity/nonmyeloablative conditioning regimen; and PBSCs, peripheral blood stem cells.